EBS Emergent BioSolutions Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1367644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-17.7%
TTM net income YoY-443.5%
TTM EPS YoY-475.0%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—
Margins
Gross margin48.4%
Operating margin-27.7%
Net margin-40.2%
FCF margin29.0%
EBITDA margin-18.4%
Returns
ROE-58.2%
ROA-21.2%
ROIC (approx.)-17.3%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets68.5%
Debt / equity1.62x
Current ratio4.58x
Interest coverage-3.96x
Cash quality & payout
Operating cash flow / net income-0.77x
Accruals ratio-37.5%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $110.00M | $234.30M | $156.10M | $148.70M | $231.10M | $140.90M | $222.20M | $194.70M |
| Cost of revenue | $80.80M | $97.10M | $72.00M | $84.90M | $85.90M | $66.90M | $88.50M | $118.00M |
| Gross profit | $29.20M | $137.20M | $84.10M | $63.80M | $145.20M | $74.00M | $133.70M | $76.70M |
| R&D expense | $9.40M | $9.20M | $10.50M | $12.10M | $13.50M | $12.50M | $15.10M | $9.10M |
| SG&A expense | $46.50M | $44.60M | $46.60M | $51.10M | $38.90M | $43.70M | $52.40M | $60.80M |
| Operating income | -$37.30M | -$125.10M | $10.50M | -$27.90M | $76.50M | $1.60M | $49.90M | -$9.50M |
| Interest expense | $9.70M | $10.00M | $11.00M | $14.70M | $15.20M | $14.70M | $14.70M | $14.80M |
| Pretax income | -$36.40M | -$166.30M | $13.40M | -$50.70M | $57.60M | -$16.80M | $92.70M | -$27.60M |
| Income tax | -$3.70M | $13.90M | $6.60M | $3.90M | $6.40M | -$4.80M | $24.70M | $3.70M |
| Net income | -$32.70M | -$180.20M | $6.80M | -$54.60M | $51.20M | -$12.00M | $68.00M | -$31.30M |
| EBITDA | -$30.90M | -$118.30M | $34.00M | -$4.40M | $83.60M | $8.90M | $75.30M | $16.50M |
| EPS (basic) | -0.64 | -3.49 | 0.13 | — | 0.96 | -0.22 | 1.25 | — |
| EPS (diluted) | -0.64 | -3.49 | 0.07 | — | 0.91 | -0.22 | 1.19 | — |
| Weighted avg. shares (diluted) | 51.30M | 51.60M | 56.50M | — | 56.50M | 54.20M | 57.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $175.70M | $139.70M | $160.30M | $205.40M | $245.50M | $267.30M | $149.10M | $105.60M |
| Receivables | $77.50M | $190.00M | $121.60M | $84.20M | $149.50M | $79.80M | $203.70M | $154.50M |
| Inventory | $280.90M | $303.60M | $327.60M | $343.40M | $356.30M | $338.60M | $314.00M | $311.70M |
| Current assets | $558.20M | $666.00M | $637.60M | $662.50M | $786.90M | $719.50M | $706.80M | $598.70M |
| PP&E, net | $174.80M | $178.00M | $199.40M | $205.40M | $209.80M | $216.10M | $221.00M | $270.60M |
| Goodwill | — | — | — | $0 | — | — | — | $0 |
| Intangibles | $252.50M | $261.80M | $470.40M | $436.50M | $452.70M | $469.00M | $485.20M | $501.50M |
| Total assets | $995.20M | $1.12B | $1.32B | $1.32B | $1.46B | $1.42B | $1.43B | $1.39B |
| Current liabilities | $122.00M | $122.80M | $148.70M | $132.20M | $136.50M | $127.10M | $111.90M | $162.40M |
| Short-term debt | — | — | — | — | — | — | — | $0 |
| Long-term debt | $507.70M | $581.80M | $573.60M | $572.10M | $663.10M | $667.80M | $665.70M | $663.70M |
| Total debt | $507.70M | $581.80M | $573.60M | $572.10M | $663.10M | $667.80M | $665.70M | $663.70M |
| Total liabilities | $682.00M | $775.40M | $797.30M | $796.00M | $878.50M | $880.90M | $873.40M | $906.90M |
| Shareholders' equity | $313.20M | $341.40M | $523.10M | $522.60M | $582.50M | $536.20M | $552.70M | $482.80M |
| Net debt | $332.00M | $442.10M | $413.30M | $366.70M | $417.60M | $400.50M | $516.60M | $558.10M |
| Shares outstanding | 51.30M | 51.30M | 51.80M | 52.10M | 52.70M | 53.70M | 54.50M | 54.30M |
| Cash flow statement | ||||||||
| Operating cash flow | $100.10M | $56.10M | -$33.80M | $77.70M | -$2.30M | $106.40M | -$11.20M | -$79.90M |
| Capital expenditure | $3.30M | $2.10M | $2.40M | $3.90M | $3.40M | $2.90M | $3.60M | $1.70M |
| Free cash flow | $96.80M | $54.00M | -$36.20M | $73.80M | -$5.70M | $103.50M | -$14.80M | -$81.60M |
| Investing cash flow | $4.60M | -$52.30M | -$2.40M | -$3.90M | -$3.40M | $17.20M | $59.50M | $28.60M |
| Financing cash flow | -$68.70M | -$24.40M | -$11.40M | -$113.90M | -$15.90M | -$6.40M | -$400,000 | $500,000 |
| Depreciation & amortization | $6.40M | $6.80M | $23.50M | $23.50M | $7.10M | $7.30M | $25.40M | $26.00M |
| Stock-based compensation | $4.20M | $6.90M | $1.90M | $5.30M | $4.80M | $4.60M | $1.50M | $4.30M |
| Share buybacks | $100,000 | $9.00M | $9.00M | $9.10M | $8.90M | $6.90M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.